MultiStem for the Treatment of Acute Respiratory Distress Syndrome

A clinical trial is testing whether an adult stem cell therapy can help people survive the most severe form of lung failure. Acute respiratory distress syndrome (ARDS) is a life-threatening condition in which the lungs become inflamed and fill with fluid, making it impossible to breathe without a ventilator. Current treatment is largely supportive, and mortality remains high. This phase 1/2 trial, called MUST-ARDS, investigates MultiStem, an allogeneic adult stem cell therapy already in phase 2 trials for stroke and ulcerative colitis. Unlike traditional cell therapies that replace damaged cells, MultiStem works by releasing factors that regulate the immune system, protect injured tissue, promote repair, and stimulate new blood vessel growth. If the trial shows MultiStem can reduce mortality, shorten hospital stays, and improve patient outcomes, it could offer a new treatment option for a condition that currently has none. The therapy is being developed by Athersys, a small biotechnology company, in partnership with the Cell Therapy Catapult. Success would mean a drug-like cell therapy that could be given off-the-shelf to patients with ARDS, potentially changing how intensive care units manage this devastating lung injury.